Compared with other B-cell inhibitors, telitacicept can affect B-cell differentiation at multiple sites by inhibiting the binding of BAFF and APRIL (6), and its efficacy and safety have been demonstrated in clinical studies on systemic lupus erythematosus (SLE) phase II and III, IgA Nephropathy (IgAN) phase II, and pSS phase II. The gene discussed is TNFSF13; the disease is systemic lupus erythematosus.